A052020 Stock Overview
A biopharmaceutical company, develops medicines in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
STCube, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,190.00 |
| 52 Week High | ₩12,700.00 |
| 52 Week Low | ₩4,350.00 |
| Beta | -0.029 |
| 11 Month Change | 8.79% |
| 3 Month Change | 32.83% |
| 1 Year Change | -38.22% |
| 33 Year Change | -26.13% |
| 5 Year Change | -46.64% |
| Change since IPO | 45.65% |
Recent News & Updates
Shareholder Returns
| A052020 | KR Electronic | KR Market | |
|---|---|---|---|
| 7D | 0.5% | -4.9% | -0.5% |
| 1Y | -38.2% | -15.2% | 7.3% |
Return vs Industry: A052020 underperformed the KR Electronic industry which returned -15.2% over the past year.
Return vs Market: A052020 underperformed the KR Market which returned 7.3% over the past year.
Price Volatility
| A052020 volatility | |
|---|---|
| A052020 Average Weekly Movement | 10.6% |
| Electronic Industry Average Movement | 7.1% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 3.6% |
Stable Share Price: A052020's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A052020's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 16 | Hyunjin Jung | www.stcube.com |
STCube, Inc., a biopharmaceutical company, develops medicines in South Korea. The company develops anti-cancer immunotherapeutic drugs and anti-viral drugs. It offers platform technologies, which include In vivo RNAi ICP target discovery platform for exploring material ICP target; glycosylation-specific antibody development platform for development of antibodies that mask glycosylation sites on target proteins; and ICP functional assay platform for development of various in vivo/in vitro analytical/experimental methods.
STCube, Inc. Fundamentals Summary
| A052020 fundamental statistics | |
|---|---|
| Market cap | ₩288.80b |
| Earnings (TTM) | -₩22.12b |
| Revenue (TTM) | ₩7.66b |
37.7x
P/S Ratio-13.1x
P/E RatioIs A052020 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A052020 income statement (TTM) | |
|---|---|
| Revenue | ₩7.66b |
| Cost of Revenue | ₩7.26b |
| Gross Profit | ₩403.31m |
| Other Expenses | ₩22.52b |
| Earnings | -₩22.12b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -474.01 |
| Gross Margin | 5.26% |
| Net Profit Margin | -288.69% |
| Debt/Equity Ratio | 0% |
How did A052020 perform over the long term?
See historical performance and comparison